Representing 18%-19% growth compared to first quarter 2024 revenue. The strong growth experienced in the first quarter of 2025 was driven by orthobiologics and licensing revenue.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability
- Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans
- Xtant Medical price target lowered to $2 from $3 at BTIG
- Xtant Medical Reports Strong 2024 Revenue Growth
- XTNT Earnings this Week: How Will it Perform?